Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

September 25, 2020

In Re: Aimmune Therapeutics, Inc. Securities Litigation

Track this case

Case Number:

3:20-cv-06733

See also:

Court:

California Northern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Maxine M. Chesney

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 21, 2025

    Aimmune Investors' $27.5M Deal In Nestle Suit Gets Final OK

    Investors in biopharmaceutical company Aimmune Therapeutics Inc. have gotten final approval for their $27.5 million deal resolving claims the company was falsely undervalued before its merger with Nestlé Health Science SA.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login